Core Viewpoint - Multiple companies in China conducted share buybacks on October 17, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1][2] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 10.70 million shares for a total of 494 million yuan, with a year-to-date total of 27.30 million shares, representing 0.110% of its total share capital [2] - Four Seasons Pharmaceutical (00460) repurchased 15 million shares for 21.76 million yuan, with a year-to-date total of 59.60 million shares, representing 0.647% of its total share capital [2] - Mengniu Dairy (02319) repurchased 1.20 million shares for 16.97 million yuan, with a year-to-date total of 18.52 million shares, representing 0.473% of its total share capital [2] Group 2: Other Notable Buybacks - VITASOY International (00345) repurchased 1.02 million shares for 8.20 million yuan, with a year-to-date total of 566.60 million shares, representing 0.540% of its total share capital [2] - Zhongtong Express-W (02057) repurchased 445,000 shares for 8.41 million yuan, with a year-to-date total of 5.07 million shares, representing 0.630% of its total share capital [2] - Huazhong Media (00685) repurchased 500,000 shares for 50,000 yuan, with a year-to-date total of 225.60 million shares, representing 0.139% of its total share capital [2]

Core Viewpoint - Hema Medical (03309) announced a share buyback plan, spending HKD 381,400 to repurchase 200,000 shares at a price range of HKD 1.89 to HKD 1.92 per share [1] Summary by Category - **Company Actions** - The company will repurchase 200,000 shares at a total cost of HKD 381,400 [1] - The buyback price per share is set between HKD 1.89 and HKD 1.92 [1]

Core Viewpoint - The company, 希玛医疗 (03309), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 200,000 shares at a total cost of HKD 381,400 [1] - The buyback price per share ranges from HKD 1.89 to HKD 1.92 [1]

Group 1 - The company, Hema Medical (03309.HK), announced a share buyback on October 17, 2025, costing HKD 381,000 to repurchase 200,000 shares [1] - The buyback price per share ranged from HKD 1.89 to HKD 1.92 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年10月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on October 16, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 192 million [1] - Mengniu Dairy (02319) repurchased 1 million shares for 14.44 million [2] - Yun Gongchang (N23027) repurchased 2.01 million shares for 8.19 million [2] Group 2: Cumulative Buyback Data - Xiaomi Group-W has a cumulative buyback of 16.59 million shares, representing 0.060% of total share capital [2] - Mengniu Dairy has a cumulative buyback of 17.32 million shares, representing 0.443% of total share capital [2] - Yun Gongchang has a cumulative buyback of 20.62 million shares, representing 4.483% of total share capital [2] Group 3: Other Notable Buybacks - Lianyi Rong Technology-W (09959) repurchased 2.39 million shares for 7.48 million, with a cumulative total of 60.47 million shares, representing 2.830% of total share capital [2] - Kangning Jiere Pharmaceutical-B (09966) repurchased 400,000 shares for 5.48 million, with a cumulative total of 801,000 shares, representing 0.083% of total share capital [2] - Guisheng Tongqiao-B (02190) repurchased 50,000 shares for 1.24 million, with a cumulative total of 330,350 shares, representing 1.009% of total share capital [2]

智通财经APP讯，希玛医疗(03309)发布公告，于2025年10月16日，该公司斥资54.57万港元回购28万 股。 ...

Core Viewpoint - The company, 希玛医疗 (03309), announced a share buyback of 280,000 shares at a cost of HKD 545,700 on October 16, 2025 [1] Group 1 - The total amount spent on the share buyback is HKD 545,700 [1] - The number of shares repurchased is 280,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年10月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Summary by Sections Southbound Fund Holdings - On October 15, southbound funds reduced their holdings by 88,000 shares, marking a decrease of 0.11% [2]. - Over the past five trading days, there has been a cumulative net reduction of 1,242,000 shares, with reductions occurring on all five days [1][2]. - In the last 20 trading days, the total net reduction reached 3,440,000 shares, with reductions on all 20 days [1]. Current Holdings - As of now, southbound funds hold 80,083,000 shares of Hema Medical, which represents 6.37% of the company's total issued ordinary shares [1]. Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: - The Hong Kong medical division focuses on ophthalmology, dentistry, and other medical services, along with the sale of vision aids [2]. - The mainland dental division provides dental services in mainland China [2]. - The medical consumables sales division operates in Hong Kong [2]. - The mainland ophthalmology division offers ophthalmic services and sells vision aids in mainland China [2].